The QMSR Era: FDA’s Final Move to ISO 13485 Harmonization - Quality Management System and the FDA
- SANRUBIO, LLC
- 4 days ago
- 2 min read
The transition period has ended. As of February 2, 2026, the FDA’s Quality Management System Regulation (QMSR) is the mandatory standard for all medical device manufacturers selling in the United States. By incorporating ISO 13485:2016 by reference, the FDA has effectively dismantled the dual-system burden that plagued the industry for decades.
What has changed?
Quality Management System and the FDA: The QMSR is not just a name change; it is a structural shift in how quality is audited:
Risk Management at the Core: Unlike the old QS Regulation, the QMSR explicitly adopts ISO 13485’s focus on risk management throughout the entire product lifecycle, not just in design controls.
Global Language: Terms like "Design History File (DHF)" and "Device Master Record (DMR)" are now being integrated into the broader ISO documentation framework, though their functional requirements remain.
Audit Efficiency: The FDA will now conduct inspections using a process that aligns more closely with the Medical Device Single Audit Program (MDSAP).
The "FDA Plus" Factors - Specific Requirements
It is a common mistake to think that ISO 13485 certification is now a "pass" into the U.S. market. The FDA has maintained specific requirements that go beyond the ISO standard:
Reporting and Records: Requirements under 21 CFR 803 (MDR) and 21 CFR 806 (Corrections and Removals) remain unique to the FDA.
Labeling Controls: Specific U.S. labeling regulations still apply.
Traceability: For certain high-risk devices, the FDA maintains stricter traceability mandates than the baseline ISO standard.
Strategic Advantage
For manufacturers already operating under ISO 13485 in Europe or Asia, the U.S. market is now more accessible than ever. The alignment reduces the "regulatory tax" of maintaining two separate quality manuals, allowing teams to focus on innovation rather than administrative duplication.
Conclusion
The implementation of the QMSR marks the dawn of a truly globalized medical device industry. While the FDA continues to exercise its independent authority, the move to ISO 13485:2016 provides a common language for quality. For Sanrubio Medical Devices Consulting, the advice is clear: if your QMS isn't yet fully aligned with the risk-based approach of ISO 13485, you are not just behind on paperwork—you are behind on the law.
At Sanrubio, LLC, strategically supporting manufacturers from the U.S., Latin America, Europe, and Asia, we offer:
Medical Device Establishment Registration Renewal
Personalized regulatory advice: from Pre-Submission design to 510(k) submission (Pre-market notification), De Novo Devices submission, and QMSR consulting.
Strategic location: in Miami, key hub for foreign manufacturers entering the U.S. market.
Free initial consultancy: analyze your case with us and optimize your regulatory strategy.
Ready to bring your Medical Devices to the U.S. market?
Contact us for a free personalized consult and move ahead with confidence in your regulatory journey.
Comments